JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Smith & Nephew PLC ADR

Fermé

30.38 -2.25

Résumé

Variation du prix de l'action

24h

Actuel

Min

30.34

Max

31.06

Chiffres clés

By Trading Economics

Revenu

35M

331M

Ventes

203M

3.2B

P/E

Moyenne du Secteur

22.441

67.147

Rendement du dividende

2.44

Marge bénéficiaire

10.368

Employés

16,988

EBITDA

133M

856M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+2.96% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.44%

2.36%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.5B

14B

Ouverture précédente

32.63

Clôture précédente

30.38

Score Technique

By Trading Central

Confiance

Bullish Evidence

Smith & Nephew PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 avr. 2026, 23:53 UTC

Résultats

Naver Posts Weaker First-Quarter Earnings

29 avr. 2026, 23:41 UTC

Actions en Tendance

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 avr. 2026, 23:55 UTC

Résultats

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 avr. 2026, 23:54 UTC

Résultats

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 avr. 2026, 23:52 UTC

Résultats

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 avr. 2026, 23:51 UTC

Résultats

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 avr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 avr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 avr. 2026, 23:22 UTC

Résultats

China Longyuan 1Q Net CNY1.70B, Down 14%

29 avr. 2026, 23:22 UTC

Résultats

China Longyuan: Power Generation Down 2.9% as of End-March

29 avr. 2026, 23:20 UTC

Résultats

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 avr. 2026, 23:20 UTC

Résultats

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Loss Narrows>000002.SZ

29 avr. 2026, 23:18 UTC

Résultats

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 avr. 2026, 23:17 UTC

Résultats

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 avr. 2026, 23:15 UTC

Résultats

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 avr. 2026, 23:15 UTC

Résultats

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 avr. 2026, 23:13 UTC

Résultats

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 avr. 2026, 23:12 UTC

Résultats

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 avr. 2026, 23:11 UTC

Résultats

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 avr. 2026, 23:11 UTC

Résultats

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 avr. 2026, 23:04 UTC

Résultats

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 avr. 2026, 23:04 UTC

Résultats

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparaison

Variation de prix

Smith & Nephew PLC ADR prévision

Objectif de Prix

By TipRanks

2.96% hausse

Prévisions sur 12 Mois

Moyen 32 USD  2.96%

Haut 32 USD

Bas 32 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

1 ratings

0

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

26.64 / 28.37Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat